Fibrosis represents a pathophysiological condition intrinsic to chronic and progressive diseases, which is characterized by excessive tissue scarring. Diseases associated with fibrosis include cardiac fibrosis, metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel diseases (IBD), chronic kidney disease (CKD), pulmonary fibrosis and scleroderma, collectively responsible for a large percentage of global morbidity and mortality. Significant progress has been made in our understanding of the mechanisms of fibrosis, different etiologies and therapeutic implications. Recently, several anti-fibrotic drugs have been approved for pulmonary and liver fibrosis. However, there remains a gap to identify effective treatments of fibrosis. This may be due to a the limited number of identified druggable putative targets, lack of translational research and insufficient disease models. This year’s Keystone Symposia Fibrosis Conference will discuss the viewpoint of biologists, physician-scientists and industry collaborators from around the globe on fibrosis and its intricacy to deterioration of organ function in multiple diseases. We propose the following specific goals: 1. Address gaps in knowledge in mechanisms of fibrosis across organs 2. Discuss challenges for diagnosis and monitoring of fibrosis progression in patients with chronic fibrotic diseases 3. Discuss models and pathways to effectively translate mechanisms of fibrogenesis into effective therapies 4. Train scientists of all levels of seniority in the area of fibrosis and provide opportunities for mentoring junior scientists. The goals of the symposium will be accomplished by putting together outstanding invited lectures, abstract presentations, workshops, poster-sessions and in-depth discussions between the scientists. Anticipated outcomes include a rich and unparalleled scientific exchange and discussion, provision of a forum for academic with industry interaction as well as interdisciplinary exchange and collaborations spanning multiple organ systems. We expect sharing of novel methods to translate novel therapies into patients, building connections for mentorship of the next generation of scientists and ultimately an acceleration of translation of novel anti-fibrotic therapies into clinical practice. This long-standing symposium series is the only conference of its kind to bring together interdisciplinary scientists and investigators from the bench to the bedside together with industry. Traditionally this meeting series functioned as the origin of novel research paradigms in fibrosis. The anticipated pairing with the stromal biology meeting represents a synergistic overlap and is very welcome.